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The x-ray structure of an enzyme is taken into account, when available, as the refer-
ence model to explain catalytic activity and selectivity. Unfortunately, in most of the
cases the structure is available only as apostructure, i.e. without the substrate bound to
the active site, and it is strange to find many different enzyme-substrate complexes of a
specific enzyme as crystals. Moreover this structure is not the "real" structure of the pro-
tein during catalysis as the crystal is stationary.
In this paper we propose the use of CoMFA models to evaluate the differences be-
tween the crystal and the real structure of the enzyme under reaction conditions.
In addition to the stationary nature of a crystal, the experimental limitations of
crystallographic techniques to obtain crystals in a fast and reliable manner, give a
chance to the creation of CoMFA models by evaluating the easy to obtain catalytic
properties of enzyme variants to provide information about the structural changes pro-
duced by the mutations. By means of the evaluation of different structures as substrates
CoMFA models will not only provide information about the structure of the enzyme, but
also about the flexibility and potential conformational changes of the substrate binding
site.
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Introduction
Comparative Molecular Fields Analysis
(CoMFA) is a method for 3D quantitative struc-
ture-activity relationships (3D-QSAR) developed at
Tripos. Although the concept of the approach has
been known as DYLOMMS (dynamic lattice-ori-
ented molecular modelling system)1 for over a de-
cade, it was not until 90s that the method became
widely used after it was named as CoMFA in
1988.2-3 The methodology has been patented and
the program is available as a QSAR package in
SYBYL (Tripos Inc.; 1699 South Handley Rd., St.
Louis, MO 63144).
Comparative Molecular Field Analysis (CoMFA),
applied to enzyme-catalyzed biotransformations as
a 3D-QSAR methodology, may picture a semi-
quantitative structure of the active site. CoMFA has
proven its ability to predict biological properties of
systems not amenable to direct analysis. The funda-
ments of this methodology are well described in the
literature4–10 but CoMFA has been applied only a
few times in biocatalysis.11–12 The CoMFAmodel of
an enzyme is a 3D representation of the steric and
electrostatic zones of the active site, and it is
directly related to the structure of the enzyme,
when the alignment of the substrates is based on
their real docking poses. The alignment of the lig-
ands in the proper orientation is the critical step of
3D-QSAR/CoMFA analysis. In biocatalysis, the
model is built according to the conversions ob-
tained in the experimental reactions as a measure-
ment of the enzyme-substrate affinity.
In this article the aim of the authors is to ex-
plain in a comprehensive way some potential utili-
ties of the models to improve the understanding of
enzyme structure and mechanism:
i) Application of the models, based upon em-
pirical data, to properly dock substrates into the
binding site of the enzyme.
ii) Creation of homology models taking into
account catalytic data and not only structural simi-
larities at the protein level.
iii) Comparison of different biocatalysts ac-
cording to their substrate selectivity.
iv) Development of new approaches: A method,
based on the statistical regression of the CoMFA
models from different related enzymes or enzyme
mutants is also proposed (Crosslink-CoMFA
(Cr-CoMFA)).
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Development of the Crosslink CoMFA
(Cr-CoMFA) approach
A collection of 416 micro-organisms from dif-
ferent taxonomic groups were tested versus a de-
signed series of carbonylic compounds (Fig 1) in a
hierarchical screening process looking for new ac-
tive alcohol dehydrogenases.13-14 From this work
two filamentous fungi, Diplogelasinospora grovesii
IMI 17018, Gongronella butleri CBS 157.25, and
two yeasts, Schizosaccharomyces octosporus
NCYC 427 and Geotrichum candidum NCYC 49,
were selected due to their activity in the reduction
of different compounds (Table 1).
From these data a 3D-QSAR/CoMFA model of
each individual biocatalyst was generated selecting
the alignment criteria explained in Fig 2. In every
case q2 (regression coefficient; over 0.5 the model is
considered predictive) values over 0.5 were ob-
tained. The statistical values from these analyses
are shown in Table 2 and the CoMFA model ob-
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F i g . 1 – Chemical structures of most of the carbonylic compounds used as substrates
F i g . 2 – Criteria used for the alignment of the substrates.
Using MULTIFIT within SYBYL® the molecules were aligned
by different ways. The template substrate used for the study
was 2-adamantanone. The best results were achieved superim-
posing the C = O to be reduced, then the bulkier part of the
molecule is located in the X>0 (right) and the less voluminous
in the X<0 (left) according to a coordinate system.
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T a b l e 1 – Results obtained using the selected microbial strains vs. the collection of substrates. [Substrate] = 2.5 m mol dm–3,
250 min–1, 28 °C, 48 h. The results are represented as conversion (%) of product (alcohol).
N Substratea D. grovesii G. butleri. S. octosporus G. candidum
1 benzaldehyde 0 95 98 0
2 2-furaldehyde 98 98 0 0
3 R-myrtenal 73 90 42 0
4 tetradecanal 0 0 0 0
5 2-acetylfurane 0 11 39 80
6 2-acetylpyridine 14 13 73 0
7 cyclobutanone 77 67 10 0
8 cyclopentanone 14 33 2 0
9 cyclohexanone 85 96 87 36
10 cycloheptanone 9 26 8 0
11 cyclooctanone 0 18 0 0
12 cyclododecanone 0 25 0 0
13 4R-carvone* 90 87 65 77
14 4S-carvone* 93 51 60 82
15 (1R,4R)-dihydrocarvone 79 88 75 76
16 2-azetidinone 10 6 0 0
17 4-acetoxi-azetidin-2-one 12 0 0 0
18 1-decalone 90 65 34 76
19 (4aR, 8aR)-cis-1-decalone 43 36 3 86
20 (4aS, 8aS)-cis-1-decalone 86 77 11 90
21 (4aR, 8aS)-trans-1-decalone 96 71 8 41
22 (4aS,8aR)-trans-1-decalone 96 86 14 92
23 2-decalone 65 57 75 72
24 (4aR,8aS)-cis-2-decalone 81 0 86 20
25 (4aS,8aR)-cis-2-decalone 24 65 90 26
26 (4aR,8aR)-trans-2-decalone 70 26 72 25
27 (4aS,8aS)-trans-2-decalone 73 12 18 5
28 -tetralone 0 6 9 5
29 4-methyl-decal-2-en-1-one 3 1 0 0
30 4aR-methyl-decal-2-one 3 2 0 0
31 2-adamantanone 58 98 22 12
32 bicyclo-[3.3.1]-nonan-9-one 39 95 32 16
33 bicyclo-[3.2.1]-octan-2-one 74 32 10 0
34 R-fenchone 0 0 0 0
35 cis-bicyclo-[3.2.0]-hept-2-en-6-one 20 44 24 0
36 trans-bicyclo-[3.2.0]-hept-2-en-6-one 1 7 4 0
37 Verbenone 0 0 0 0
38 2-aza-bicyclo[2.2.1]hept-5-en-3-one 0 2 0 0
39 1-chloro-3-(1-naphtiloxy)-propan-2-one 99 0 93 9
40 N-[4-(3-chloro-2-oxo-propiloxi)-phenyl]-acetamida 99 98 0 0
41 1-chloro-3-(phtalimidyl)-propan-2-one 68 0 0 0
42 cis-bicyclo[3.3.0]octan-3,7-dione 0 0 0 0
43 acetyl-ferrocene 0 0 0 0
44 1-phenyl-propano-1,2-dione 93 2 0 0
45 cholesten-3-one 0 0 0 0
46 4-chloro-ethyl-aceto-acetate 0 95 98 No
aThe experimental and analytical conditions for these reactions have been previously described.13-14
*R-carvone and S-carvone were not considered for the Cr-CoMFA due to the reduction of the double bond that appears to certain extent in some
of the catalyst, instead the dihydrocarvone 15 was considered.
tained from G. candidum alcohol dehydrogenase
activity is shown as example in Fig 3.
During the evaluation of the results obtained in
the reduction reactions and the CoMFA models we
realized that the pattern of substrate affinity was sim-
ilar between the different strains. Especially interest-
ing was the high activity in the reduction of
1-decalone 18 and 2-decalone 23 while no one of the
biocatalysts was able to reduce related structures as
28, 29 and 30. This fact was astonishing as far as al-
cohol dehydrogenases present in microbial strains,
distant from the taxonomic point of view, were
showing considerable similarities in substrate scope.
In the bibliography different publications point
out the structural relationships between the different
alcohol dehydrogenases and even the hypothesis
about the existence of a common ancestor,15-16
based in structural studies of different proteins of
the same family.
The hypotheses suggested by these structural
studies were similar to the conclusions reached
evaluating our biocatalytic data, this was quite in-
teresting for us and we attempt to go one step fur-
ther as a test probe, in that sense we tried to devel-
oped a methodology that we call Crosslink CoMFA
(Cr-CoMFA).
The Crosslink CoMFA approach
Cr-CoMFA is a method to obtain a model dis-
playing the common characteristics of substrate af-
finity from a series of biocatalysts. The common
pattern of substrate affinity may be obtained by the
3D statistical regression of the different single
CoMFA models using techniques as partial least
squares PLS.2,7-9 As far as we know there is not any
specific tool available for this purpose, due to this
fact we decided to face our goal using an indirect
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T a b l e 2 – Statistical parameters of the CoMFA models of the biocatalysts tested
Parameter Analysis D. grovesii G. butleri. S. octosporus G. candidum
q2 Leave one out 0.549 0.625 0.555 0.648
N° of components Leave one out 7 11 14 8
R2 No validation 0.991 1 0.995 1
F values No validation 280.575 3405 472123 66008
Prob. R2 = 0 No validation 0 0 0 0
F i g . 3 – 3D-QSAR model of G.candidum (left) and S. octosporus (right) alcohol dehydrogenase activity. The colour code is as fol-
lows: Steric hindrance zones: green areas depict zones of space where occupancy by the substrates increases affinity, whereas yellow
areas depict zones where occupancy decreases affinity. Electrostatic zones: areas where a high electron density provided by the ligand
increases (red) or decreases (blue) the activity.
method: A new data table was built containing only
the data corresponding to those substrates where
every biocatalyst presented the same catalytic be-
haviour (considering active >10 % conversion and
not active substrates where the conversion is below
5 %). The substrates selected underlined in table 1.
From this table the Cr-CoMFA model was gener-
ated with a q2 of 0.8 (Tab 3), higher than the ones
obtained for the individual models. The Cr-CoMFA
model is displayed in Figure 4, where the important
regions of steric hindrance (Lennard Jones) and
electrostatic (coulombic) effects are well defined,
displaying the overall characteristics common to all
the enzymes tested.
In summary the Cr-CoMFA model shows the
common pattern of substrate affinity of the considered
biocatalysts. In specific cases, as when considering
variants obtained from a wild-type enzyme by directed
evolution or natural enzymes from the same family
evolving from the same ancestor, the Cr-CoMFAmod-
els indicate the substrate scope characteristics con-
served during evolution. The comparison of the
CoMFA models of each enzyme and the Cr-CoMFA
model generated from them could provide additional
information to enhance our knowledge about evolution
and directed evolution, as explained afterwards.
A diagram with a graphical overview of the
Cr-CoMFA method is shown in Fig 5.
The analysis of the data from screening ap-
proaches by means of software tools like
Sybyl/CoMFA could be interesting for protein engi-
neers, especially in the case of evolutionary ap-
proaches, where is impossible to crystallize all the
structural diversity generated, but where the cata-
lytic profile, i.e. bioconversions against different
structures, is easy to obtain.
Enzyme mechanisms, CoMFA models
and x-ray structure
The protein-ligand interaction were described
at first by the key and lock theory of Emil Fischer
in 1894,17 where key (substrate) and lock (enzyme)
were considered as rigid structures. In 1958 Daniel
E. Koshland published the induced fit theory,18 pro-
posed in the following terms:19 a) The precise ori-
entation of the catalytic groups is required for en-
zyme action, b) the substrate causes an appreciable
change in the three dimensional relationship of the
amino acids at the active site, and c) the changes in
the protein structure caused by the substrate will
bring the catalytic groups into the proper alignment,
whereas a nonsubstrate will not. Subsequently, the
solvation co-solvation model20 was developed con-
sidering as well the flexibility of the substrate bind-
ing site.
The “key and lock” model was evolved to the
“hand in glove” model, which included Fischer idea
of a fit but including the flexibility concept.
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T a b l e 3 – Statistical parameters of the Cr-CoMFA model
Parameter Analysis Cr-CoMFA
q2 Leave one out 0.798
N° of components Leave one out 2
R2 No validation 0.95
F values (n1 = 2, n2 = 11) No validation 97.618
Prob. R2=0 (n1 = 2, n2 = 11) No validation 0
F i g . 4 – Cr-CoMFA model generated. Steric hindrance zones: green areas depict zones of space where occupancy by the sub-
strates increases affinity, whereas yellow areas depict zones where occupancy decreases affinity. Electrostatic zones: ar-
eas where a high electron density provided by the ligand increases (red) or decreases (blue) the activity.
Today almost every enzyme has been shown to
undergo significant ligand induced changes.21 This
potential flexibility of the substrate binding site of
the enzymes is also a limitation when using the
x-ray structure as reference even when a specific
substrate is included in the pdb file. Different sub-
strate structures shall lead to different binding site
conformations, this fact supports the idea of using
CoMFA models and fitting models (aligned sub-
strates) of the accepted structures to enhance the
understanding about the binding site behaviour, and
add new information to the pdb files (x-ray struc-




The building of 3D-QSAR/CoMFA models has
several potential utilities that justify the use of this
theoretical method for biotransformations and di-
rected evolution.
When an enzyme or library of enzymes is
screened against a collection of substrates it is not
easy to have a 3D overview of the capabilities of
the enzyme. CoMFA is a good option to display a
comprehensive model from the large amount of
data generated, that could serve as reference for the
rational interpretation of the results and, further-
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F i g . 5 – Crosslink CoMFA. Overview.
more, for the selection a priori of new potential
substrates. The results from further experiments
would provide as well new information to refine the
model.
3D-QSAR/CoMFA models and Directed
Evolution: Potential applications
The use of enzymes in organic reactions is re-
stricted due to their substrate specificity, so it could
not be assumed as a general synthetic methodology.
Nowadays, new biocatalysts could be created by di-
rected evolution enhancing the activity and selec-
tivity of a known enzyme structure22-30 and over-
coming some of the catalytical restrictions of the
natural protein. There are two general ways to face
the improvement of an enzyme characteristic by di-
rected evolution:
i) site directed mutagenesis31 (as a traditional
protein engineering method). This method is
strongly recommended when the crystal structure of
an enzyme is available and it is the ideal option
when that structure has been obtained with a refer-
ence substrate bound at the active site. Practically,
molecular biology techniques permit the substitu-
tion of a specific amino acid by another one at a de-
fined position. According to this, in site directed
mutagenesis the researcher needs detailed informa-
tion concerning the 3D structure of the active-site
of the enzyme to predict the proper amino acid sub-
stitution and information about the more convenient
amino acid to be inserted.28 3D-QSAR/CoMFA
models could provide interesting data to complete
the information required for a successful directed
evolution process based on rational design, espe-
cially, when using a homology model as reference
or when the crystal structure of the enzyme is only
available as apostructure.
ii) random mutagenesis methods32-35 as well
known error-prone PCR, are easier to perform and
strongly recommended as first step, especially
when the crystal structure or the enzyme is not
available and not reliable homology models could
be built, but with a huge problem, the library size.
This drawback can only be overcome when a selec-
tion system or a efficient high throughput screening
system are available to detect the hits.
The evaluation of the structural changes of the
enzyme mutants generated either by site-directed or
random mutagenesis, is a major point to understand
the enzyme behaviour. When it is possible to obtain
the crystal structure of the wild-type enzyme and its
mutants, critical information can be achieved.36
However, it is not a trivial thing to obtain the crys-
tal structure of the enzymes, as some enzymes are
unstable in their purified form or really difficult to
crystallize, e.g. Pseudomonas aeruginosa lipase.37
In those cases where the obtaining of the crystal is
not straight forward, the comparison of different
CoMFA models generated from the catalytic profile
of wild type and mutants may provide additional in-
formation.
a) CoMFA and site directed mutagenesis
CoMFAmodels are especially interesting when
the crystal structure of the enzyme is not available
with the substrate docked at the active site. In this
case, it is necessary to calculate the proper position
where the substrate should be located. This opera-
tion is the key step of rational design approaches in
site directed mutagenesis, as the docked substrate is
the main reference for selecting the amino acids
that shall be replaced to modify the activity or se-
lectivity of the enzyme.
Usually, a well accepted substrate is selected to
locate it into the active site as reference supported
by computational tools. Anyway, the limitation is
that, several different orientations of the substrate at
the active site could be justified. In this case
CoMFA models generated from different docking
poses may help in the proper location of the sub-
strate at the substrate binding site.
b) CoMFA and homology models: 3D-models as
reference for the creation of homology models.
The main limitation for the rational design of
the mutations appears when the enzyme of interest
does not have the x-ray structure available. In these
cases, the first recommended step is to use an er-
ror-prone PCR29,35 as a random mutagenesis
method, that create large libraries of mutants that
have to be screened afterwards. However, the dif-
ferent activities or selectivities of the enzyme vari-
ants created by random mutagenesis methods could
not be explained in the absence of a reference struc-
ture
Due to this fact, when the x-ray structure of the
enzyme is not available, a related protein of known
structure is used as template to build up a homology
model. This homology is sometimes established
taking into account the primary structure of the pro-
tein, and assuming from the beginning that the ter-
tiary structure of the enzyme could be strongly dif-
ferent. As well, it has been widely described in lit-
erature that topology and homology sometimes are
not related, so same overall structural topology
could correspond with statistically insignificant se-
quence homology.38 CoMFA models represent the
enzyme affinity to different substrates according to
i) electrostatic and steric properties and ii) organic
reactions yields, giving as a result a 3D map of the
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topology, as steric and electrostatic fields, of the ac-
tive site involved in the biotransformation process.
The comparison of the CoMFA models of the
enzyme under analysis and the homolog enzyme
used as template should provide further data about
the real homology degree of both enzymes from the
catalytic point of view. Consequently the homology
model may be refined at the active site level. This is
the fundamental region where the evolutionary ap-
proaches are successful as can be seen in the recent
reviews about directed evolution.39-43 The summary
of the work published point out that the most criti-
cal mutations in an enzyme for modifying substrate
scope, for enantioselectivity enhancement and even
for biocatalytic promiscuity,40-41 lie in a radius of
1 nm (10 Å) around the binding pocket.42-43 Nowa-
days the creation of focused libraries by rational
design is considered the most reliable approach in
directed evolution.44 From our point of view, in
the evolution of an enzyme by rational design,
amino acid positions close to the active site should
be considered first, and then remote positions. So
the way to focus over the protein structure should
follow a microscope-like approach, where the
coarse focus knob (closer mutations) has to be used
first to obtain a preliminary image (desired effect)
that could be improved using the fine focus knob
(remote mutations). The proper combination of fo-
cuses libraries (for close mutations) and random
ep-PCR approaches (looking for not expected ef-
fects far away) will lead in general to successful
results.
c) CoMFA and evolution. Enzyme ancestors
According to the divergent evolution theory the
enzymes belonging to a specific class may present a
related structure, more similar as closer they are in
evolution. Some examples can be found in the liter-
ature about enzyme families that are supposed to
evolve from a common ancestor, as alcohol de-
hydrogenases17-18,45 kinases46 peptidases, lipases,
estereases, epoxide hydrolases and other serine hy-
drolases (PLEES).47
In this paper we suggest an indirect method,
based in the use of the information provided from
the CoMFA models of different evolutionary-re-
lated enzymes, to create an interpolation model
(Cr-CoMFA) that will show the basic electrostatic
and steric regions of the active site that are com-
mon, and which ones are not; namely which ones
are conservative (critical for the activity) and
non-conservative during evolution. This could sup-
port the creation of a 3D model of a simplified en-
zyme-ancestor structure, preserved in the actual en-
zymes.
Conclusions
The combined use of x-ray structures of the en-
zymes and the CoMFA models obtained from bio-
catalytic data could be of great interest to under-
stand the real shape and the potential conforma-
tional changes of the substrate binding of the en-
zymes under reaction conditions. Due to this fact
we propose the development of a software package
able to handle the data from CoMFA, Cr-CoMFA
and derived methods. This could represent a major
improvement for protein databases as more infor-
mation about the substrate profile, as well as analo-
gies and differences between enzymes and enzyme
variants, may be available.
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